Extended Data Fig. 2: Itaconate influences abundances of TCA cycle intermediates in tissues.
From: In vivo itaconate tracing reveals degradation pathway and turnover kinetics
a, Schematic depicting an experimental overview of 13C itaconate tracing in mice with time points of tissue and plasma collections. b, Kinetic parameters after itaconate injection. c, Heat map depicting fold change of TCA cycle intermediate abundances 15 min after itaconate injection relative to control injection in diverse tissues. d, Succinate levels in different tissues. e-j, Levels of metabolites in e, kidney, f, brain, g, lung, h, liver, i, spleen, and j, heart. T1/2 - elimination halftime; Cmax - maximal plasma concentration; AUC - area under the curve. Mice were injected with 400 mg kg−1 body weight [U-13C5]itaconate. Data are presented as heatmap (c) or means ± s.e.m. (d-j) with tissue samples at 0 min (n= 4), 15 min (n = 5), and 45 min (n = 4). P values were calculated by multiple unpaired t-test (c) or two-way ANOVA with Fisher’s least significant difference (LSD) post hoc test (d-j) with *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.0001. Exact P-values are indicated in each figure panel.
